Stockreport

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio, Inc.  (IBRX) 
PDF Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumorsFirst natural killer cell-based cellular therapy study conducted in the con [Read more]